LTR PHARMA FPO
LTPStockAU
A$0.54 ▲ +8.00%
12 juin 2026
L
LTR PHARMA FPO
A$0.54 ▲ +8.00%
12 juin 2026
LTPStockAU

01 / À propos

LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australia.

Arberion
Loading market data